Ipamorelin Protocol
Selective ghrelin-receptor agonist studied for GH release with a comparatively mild side-effect profile.
- Standard dose
- 200 mcg
- Frequency
- 1–2× daily, subcutaneous
- Route
- subcutaneous
- Cycle
- 8–12 weeks
- Vial
- 5 mg
Evidence Level: Emerging Evidence
Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.
Human evidence: Included in clinical-stage GH-secretagogue development programs with published pharmacodynamic data on GH pulsatility.
Animal evidence: Preclinical selectivity studies versus other ghrelin-receptor agonists.
Introduction & Mechanism of Action
Selective ghrelin-receptor agonist studied for GH release with a comparatively mild side-effect profile.
Pentapeptide ghrelin-mimetic that stimulates pulsatile growth-hormone release from the pituitary with comparatively little effect on cortisol or prolactin versus older secretagogues like GHRP-2/6.
Receptors/targets: Ghrelin receptor (GHS-R1a)
Areas of Research Interest
- Growth-hormone release research
- Recovery studies
Benefits Reported in Research
- Growth-hormone release research
- Recovery studies
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 100–300 mcg
Reported frequency: 1–2× daily, subcutaneous
Reported cycle duration: 8–12 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Research Reference Data
Published research on Ipamorelin reports administration at 100–300 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.
| Variant | Route | Reported frequency | Reported dose |
|---|---|---|---|
| Standard Protocol | subcutaneous | 1–2× daily, subcutaneous | 200 mcg |
Reconstitution Reference
Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.
Open the research calculator, pre-filled for Ipamorelin →Research Protocol Timeline
A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.
- 01
Formulation
Supplied as a lyophilized 5 mg vial requiring reconstitution before research use.
- 02
Reconstitution Reference
Published research protocols reconstitute this vial with 2 mL bacteriostatic water to reach 2.50 mg/mL.
- 03
Reported Research Administration
Published research describes 1–2× daily, subcutaneous administration via subcutaneous route, at 200 mcg per administration.
- 04
Cycle Reference
Published protocols describe a cycle duration of 8–12 weeks. Consult a physician before beginning any new research cycle.
Dilution Guide
Reconstitute with 2 mL bacteriostatic water
Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.
Handling Guide
General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.
Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.
Storage
Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.
Monitoring
Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.
Side Effects
- Headache
- Flushing
- Injection-site reaction
- Mild water retention
Contraindications
- Active malignancy (theoretical concern given GH-axis stimulation)
- Pregnancy
Drug interactions
- Other GH-axis compounds (e.g. CJC-1295) — commonly combined; compounds the GH-pulse effect rather than being a safety conflict
Safety
- Water retention
- Theoretical effects on glucose tolerance with chronic GH-axis stimulation
Comparatively selective GH-release profile in the literature, but not an approved standalone medicine; long-term outcome data is limited.
Expected Results & Comparison
Ipamorelin is generally considered the most receptor-selective GH secretagogue in this catalog compared to GHRP-2 and GHRP-6, which show more pronounced cortisol, prolactin and appetite effects. It is commonly paired with a GHRH analog like CJC-1295 to amplify the GH pulse — a combination-based rationale rather than a "stronger vs. weaker" comparison.